Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical pharmacology study of TAS-115 drug-drug interactions in healthy male subjects
jRCT2071210113Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pamufetinib (4 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Pharmacokinetic parameters of TAS-115, digoxin, rosuvastatin, and metformin. Started Mar 2022; status: completed.
02
Drugs
pamufetinib
Beyond the preview
Go deeper on jRCT2071210113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210113.